Compare Natera Inc. Common Stock (NTRA) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Valero Energy Corporation — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Valero Energy Corporation trades at $460 (market cap $131.43B). The key difference: Valero Energy Corporation is far larger — about 2.3× Natera Inc. Common Stock's market cap, and Valero Energy Corporation pays a 1.05% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Valero Energy Corporation for 57 Days on average.
| NTRA | VLO | |
|---|---|---|
Market Cap | $57.03B | $131.43B |
Volume | 1,131,157 | 2,513,030 |
Sector | Health | Energy |
52-Week High | $425.64 | $459.78 |
52-Week Low | $179.42 | $156.39 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $56.18B | $134.90B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Valero Energy (VLO) trades at $459.78, up 5.45% today, near its 52-week high. The stock exhibits strong bullish momentum with recent earnings beats and positive technical signals. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a 56.76% buy rating, though the current price exceeds the $408.10 consensus target. Recent news highlights institutional inflows and refining margin strength.
Outlook is positive due to earnings momentum and favorable sector trends, but risks include potential policy impacts on diesel exports and high valuation multiples. The stock's proximity to resistance at $460 suggests near-term consolidation may occur. Long-term growth depends on sustaining refining margins and cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
